相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Feng Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
C. Brenner et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Glucagon-Like Peptide-1 Receptor Activation Does Not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury
Linnea Eriksson et al.
JOURNAL OF VASCULAR RESEARCH (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Jixin Zhong et al.
JOURNAL OF DIABETES RESEARCH (2015)
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway
Yao Dai et al.
ACTA DIABETOLOGICA (2014)
Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
Julie A. Lovshin et al.
CANADIAN JOURNAL OF DIABETES (2014)
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Yuichi Terawaki et al.
CARDIOVASCULAR DIABETOLOGY (2014)
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
Yanmei Zeng et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Angelo Avogaro et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits
Manar A. Nader
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2014)
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
Yuko Tashiro et al.
PEPTIDES (2014)
Human Apolipoprotein A-II Protects Against Diet-Induced Atherosclerosis in Transgenic Rabbits
Yao Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins
Masashi Shiomi et al.
ATHEROSCLEROSIS (2013)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury
Yoichiro Hirata et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes
Tetsurou Ikeda et al.
PLOS ONE (2013)
Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
Michishige Terasaki et al.
PLOS ONE (2013)
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Daisuke Shiraishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice
F. Vittone et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice
Junichi Matsubara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice
Michishige Terasaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
Soo Lim et al.
PLOS ONE (2012)
Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
Hiromasa Goto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
Nga N. Ta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Acyl-coenzyme A: cholesterol acyltransferases
Ta-Yuan Chang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
ATP-binding cassette cholesterol transporters and cardiovascular disease
John F. Oram et al.
CIRCULATION RESEARCH (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia
M Sata et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2000)
The comparative pathobiology of atherosclerosis and restenosis
JL Orford et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
分享论文
